Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial
Pozniak, Anton, Dr, Markowitz, Martin, Prof, Mills, Anthony, MD, Stellbrink, Hans-Juergen, MD, Antela, Antonio, MD, Domingo, Pere, Prof, Girard, Pierre-Marie, MD, Henry, Keith, Prof, Nguyen, Thai, MD, Piontkowsky, David, MD, Garner, Will, PhD, White, Kirsten, PhD, Guyer, Bill, PharmD
Published in The Lancet infectious diseases (01.07.2014)
Published in The Lancet infectious diseases (01.07.2014)
Get full text
Journal Article